CIK 0000908259
- Non-accelerated filer
- Smaller reporting company
Oncotelic Therapeutics, Inc.
Sign in to watch- Ticker
- OTLC
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 133679168
- Phone
- +1 650-635-7000
- Business address
- 29397 AGOURA RD., #107, AGUORA HILLS, CA, 91301
- Former names
- MATEON THERAPEUTICS INC, OXIGENE INC
- 4 Grant or award Director acquired 40,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 25,000 shares at an average $4.58 ($114,403)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award President and CEO acquired 250,000 shares (grant or award)
- 4 Open-market buy Director bought 65,800 shares at $4.94 ($325,052)
- 4 Open-market buy Director bought 100,000 shares at $5.02 ($502,000)
- 4 Open-market buy Director bought 15,000 shares at an average $4.27 ($64,024)
- 4 Returned to the company Director returned 20,000 shares (to the company)
- 4 Open-market buy President and CEO bought 45,464 shares at an average $4.09 ($185,837)
- 4 Open-market buy Director bought 84,200 shares at an average $3.49 ($294,146)
- 4 Open-market buy Director bought 12,403 shares at $3.23 ($40,062)
- 4 Open-market buy President and CEO bought 20,000 shares at an average $3.30 ($65,950)
- 4 Open-market buy Director bought 47,597 shares at an average $3.22 ($153,368)
- 4 Open-market buy Director bought 50,000 shares at $3.07 ($153,715)
Page 11 of 17 · 325 filings